JPMorgan raised the firm’s price target on Ideaya Biosciences to $35 from $32 and keeps an Overweight rating on the shares. The analyst updated biotechnology models following the ESMO presentations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences announces expansion of darovasertib, crizotinib combination
- Stifel disagrees with negative reaction in Ideaya shares after Amgen data
- Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK
- Ideaya Biosciences participates in a conference call with JPMorgan